BioMarin Pharmaceutical Inc.
BMRN
#1675
Rank
$12.700 B
Marketcap
United States
Country
$65.61
Share price
-5.66%
Change (1 day)
17.39%
Change (1 year)
Categories
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal…
Key Metrics
Trailing P/E
174.95
Forward P/E
9.90
EPS (TTM)
$0.37
Forward EPS
$6.63
Price / Book
1.98
EV / EBITDA
24.6x
Beta
0.24
Dividend Yield
—
Return on Equity
1.18%
Return on Assets
3.26%
Debt / Equity
66.47
Current Ratio
2.39
Gross Margin
50.97%
Operating Margin
21.16%
Net Profit Margin
2.14%
Free Cash Flow
$85.157M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 18 – Sep 16
-3.37%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$3.221B
Latest Net Income$348.901M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare BioMarin Pharmaceutical Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
BMRN
No recent news available. Set FINNHUB_API_KEY to enable news.
